If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Instem ALPHADAS Contract Wins

14 May 2015 07:00

RNS Number : 1232N
Instem plc
14 May 2015
 



 

Instem plc("Instem" or "the Group")

 

Instem ALPHADAS Contract Wins

 

Instem plc (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces that it has won three contracts for its ALPHADAS product suite worth approximately ÂŁ1.4 million.

 

The three new contract wins across mainland Europe, Canada and the USA comprise two new customers and an expansion contract with an existing customer. Instem will deploy the ALPHADAS product suite on one additional site for the existing customer and across eight sites with the two new customers. As the majority of the total ÂŁ1.4 million contract value comprises perpetual license fees, professional services and ongoing maintenance, it is expected that most of this revenue will be recognised in the current financial year.

 

Instem entered the Early Phase Clinical market in 2013 with the acquisition of Logos Technologies and their product suite ALPHADAS. Since the acquisition, ALPHADAS revenue has grown strongly and is now a core offering of the Group.

 

Phil Reason, CEO of Instem plc, commented: "These three new contract wins evidence the improving market backdrop in PreClinical that we have been experiencing over the past twelve months, which has now stimulated increased activity in the Early Phase Clinical market. We believe we won these contracts, with both new and existing clients, due to our comprehensive product suite in combination with the market leading expertise of our clinical team and the overall strength of the Group."

 

We believe that these contract wins are likely to stimulate further ALPHADAS opportunities and therefore we look forward with optimism for the current financial year."

 

 

For further information, please contact:

Instem plc

Tel: +44 (0) 1785 825 600

Phil Reason, CEO

www.instem.com

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or

Paul Cornelius

instem@walbrookpr.com

Sam Allen

 

Helen Cresswell

 

 

 

 

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with an additional location in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAPSDFLXSEFF
Date   Source Headline
8th Sep 20232:15 pmRNSForm 8.3 - Instem plc
8th Sep 20232:00 pmRNSForm 8 (OPD) - Instem plc
8th Sep 20231:58 pmPRNForm 8.3 - Instem Plc
8th Sep 20239:50 amRNSForm 8.5 (EPT/RI)
7th Sep 20233:03 pmRNSForm 8.3 - Instem plc
7th Sep 20233:00 pmBUSForm 8.3 - INS LN
7th Sep 20231:54 pmPRNForm 8.3 - Instem Plc
7th Sep 202311:07 amRNSForm 8.3 - Instem Plc
7th Sep 202310:12 amRNSForm 8.5 (EPT/RI)
5th Sep 20236:00 pmRNSReplacement: Form 8 (OPD) - Instem plc
5th Sep 20234:15 pmRNSForm 8 (OPD) - Instem plc
5th Sep 20231:38 pmPRNForm 8.3 - Instem Plc
5th Sep 202310:48 amRNSForm 8.5 (EPT/RI)
5th Sep 20239:55 amRNSForm 8.3 - Instem Plc
4th Sep 20234:50 pmRNSForm 8.3 - Instem plc
4th Sep 20239:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20233:00 pmBUSForm 8.3 - INS LN
1st Sep 20232:15 pmGNWForm 8.3 - Instem PLC
1st Sep 20231:29 pmPRNForm 8.3 - Instem Plc
1st Sep 202312:05 pmRNSForm 8.5 (EPT/RI)
1st Sep 202311:25 amRNSForm 8.3 - Instem plc
1st Sep 20237:00 amBUSForm 8.3 - Instem plc
31st Aug 20234:45 pmPRNRe-issue: Form 8.3 - Instem Plc
31st Aug 20233:00 pmBUSForm 8.3 - INS LN
31st Aug 202312:02 pmRNSForm 8.3 - Instem plc
31st Aug 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
31st Aug 202311:44 amGNWForm 8.3 - [Instem plc - Opening Declaration - 30 08 2023] - (CGAML)
31st Aug 202311:15 amRNSForm 8.3 - Instem PLC
31st Aug 202310:29 amGNWForm 8.3 - Instem PLC
31st Aug 202310:07 amRNSForm 8.3 - Instem Plc
31st Aug 202310:02 amBUSForm 8.3 - INSTEM PLC
31st Aug 202310:01 amRNSForm 8.3 - Instem Plc
31st Aug 20239:55 amRNSForm 8.3 - Instem plc
31st Aug 20239:44 amRNSForm 8.5 (EPT/RI)
31st Aug 20239:24 amRNSHolding(s) in Company
30th Aug 202312:09 pmRNSForm 8.3 - Instem plc
30th Aug 202311:26 amRNSForm 8.3 - Instem plc
30th Aug 202310:22 amBUSForm 8.3 - INSTEM PLC
30th Aug 202310:10 amRNSForm 8.3 - Instem Plc
30th Aug 20237:00 amRNSRecommended Cash Offer
15th Aug 20237:00 amRNSTrading Update
3rd Aug 20237:30 amRNSHolding(s) in Company
31st Jul 20231:32 pmRNSHolding(s) in Company
28th Jul 202310:00 amRNSExercise of Options, Issue of Equity & TVR
27th Jul 20231:15 pmRNSHolding(s) in Company
28th Jun 20237:00 amRNSResult of AGM
2nd Jun 20238:51 amRNSNotice of AGM & Posting of Annual Report
2nd Jun 20238:38 amRNSExercise of Options, Issue of Equity & TVR
18th May 20239:14 amRNSHolding(s) in Company
15th May 20237:01 amRNSFinal Results & Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.